The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences’ twice-yearly HIV pre-exposure prophylaxis (PrEP) med Yeztugo, ...
The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make ...
HIV pre-exposure prophylaxis (PrEP) uptake remains suboptimal among adolescents and young adults in the United States, ...
Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...
According to CDC statistics, only 25% of the approximately 1.2 million Americans who could benefit from PrEP had prescriptions in 2020. As the Bay Area Reporter has previously reported, people of ...
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that lenacapavir launches at the exact time that millions of Americans lose ...
Background: Daily, oral pre-exposure prophylaxis (PrEP) has been shown to reduce the risk of HIV. Few studies have focused on screening high-risk populations for PrEP-eligibility during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results